Dogwood Therapeutics (DWTX) Operating Income (2020 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Operating Income of -$5.1 million for Q1 2026, down 14.59% year-over-year from -$5.9 million in Q1 2025, and down 33.37% quarter-over-quarter from -$3.8 million in Q4 2025.
Dogwood Therapeutics (DWTX) Operating Income (2020 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Operating Income for 7 consecutive years, with -$5.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income fell 14.59% year-over-year to -$5.1 million; the TTM figure through Mar 2026 stood at -$28.6 million (down 86.5% YoY), while the FY2025 annual figure was -$28.0 million, down 128.74% from the prior year.
- Operating Income slipped to -$5.1 million in Q1 2026 per DWTX's latest filing, from -$3.8 million in the prior quarter.
- Across five years, Operating Income topped out at -$1.1 million in Q2 2024 and bottomed at -$15.8 million in Q3 2025.
- Historically, Operating Income has averaged -$3.7 million across 5 years, with a median of -$2.6 million in 2022.
- Annual changes were most pronounced in 2023 — Operating Income soared 60.69% — and 2025, when it plunged 587.0%.
- Dogwood Therapeutics' Operating Income stood at -$2.1 million in 2022, then soared by 45.54% to -$1.1 million in 2023, then plunged by 562.68% to -$7.5 million in 2024, then surged by 49.53% to -$3.8 million in 2025, then slumped by 33.37% to -$5.1 million in 2026.
- Business Quant data shows DWTX's Operating Income at -$5.1 million in Q1 2026, -$3.8 million in Q4 2025, and -$15.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 133.12 Mn |
| 10 | Dogwood Therapeutics | 84.64 Mn | 84.64 Mn | - | -14.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.08 Mn |
| Dec 31, 2025 | -3.81 Mn |
| Sep 30, 2025 | -15.81 Mn |
| Jun 30, 2025 | -3.92 Mn |
| Mar 31, 2025 | -4.43 Mn |
| Dec 31, 2024 | -7.54 Mn |
| Sep 30, 2024 | -2.30 Mn |
| Jun 30, 2024 | -1.07 Mn |
| Mar 31, 2024 | -1.31 Mn |
| Dec 31, 2023 | -1.14 Mn |
| Sep 30, 2023 | -1.27 Mn |
| Jun 30, 2023 | -1.48 Mn |
| Mar 31, 2023 | -1.56 Mn |
| Dec 31, 2022 | -2.09 Mn |
| Sep 30, 2022 | -2.59 Mn |
| Jun 30, 2022 | -3.67 Mn |
| Mar 31, 2022 | -3.96 Mn |
| Dec 31, 2021 | -4.19 Mn |
| Sep 30, 2021 | -4.11 Mn |
| Jun 30, 2021 | -4.28 Mn |